The combination with anti-PDL1 immunotherapy is promising because, as proven in melanoma, cGAMP would activate and recruit CD8+ T cells in the microenvironment, and cGAS seems essential for the success of PD-L1 treatment [114]. The gene discussed is CD274; the disease is melanoma.